论文部分内容阅读
目的:探讨吲哚胺吡咯2,3-双加氧酶(IDO,一种具有免疫调节作用的酶)在肾细胞癌(RCC)患者中的作用。方法:在中南大学湘雅二医院诊断为RCC的患者40例,全部接受肾切除术。肾组织的免疫病理检查采用半定量方法评估。实时定量PCR(RT-qPCR)检测RCC与非肾癌肾组织IDO的mRNA水平。免疫组织化学的方法检测血管内皮细胞的IDO蛋白表达。同时依据IDO的mRNA水平计算出患者的Kaplan-Meier生存曲线。结果:RCC肿瘤组织中IDO mRNA的表达明显高于正常肾组织(P<0.001)。在RCC患者中,IDO高表达的患者比那些低IDO表达的患者具有明显较长的生存时间(P=0.01)。统计学分析显示:RCC肿瘤组织中IDO的水平和肿瘤增殖标志物Ki67之间呈负相关,IDO水平高的患者Ki67水平低,反之亦然(P<0.01)。结论:IDO可能作为预测RCC患者预后的生物标志物。
AIM: To investigate the role of indolepyrrole 2,3-dioxygenase (IDO), an immunomodulatory enzyme, in patients with renal cell carcinoma (RCC). Methods: Forty patients with RCC diagnosed at Xiangya Second Hospital of Central South University were enrolled in this study. All patients underwent nephrectomy. Immuno-pathological examination of kidney tissue was assessed by semi-quantitative method. Real-time quantitative PCR (RT-qPCR) was used to detect mRNA levels of IDO in RCC and non-renal cancer tissues. Immunohistochemistry was used to detect IDO protein expression in vascular endothelial cells. Kaplan-Meier survival curves were also calculated based on IDO mRNA levels. Results: The expression of IDO mRNA in RCC tumor tissues was significantly higher than that in normal kidney tissues (P <0.001). Among RCC patients, IDO-overexpressing patients had significantly longer survival times (P = 0.01) than those with low IDO expression. Statistical analysis showed that there was a negative correlation between the level of IDO in tumor tissues and Ki67, a marker of tumor proliferation. Patients with high IDO levels had lower Ki67 levels and vice versa (P <0.01). Conclusion: IDO may be used as a biomarker to predict the prognosis of patients with RCC.